Ongoing important trials
BL-B01D1 (izalontamab brengitecan) — recurrent/metastatic ESCC (phase III)
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (PANKU-Esophagus01)
- Phase
- Phase III
- Recruitment
- Active, not recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT06304974
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A phase III trial is studying a dual-target antibody that carries a cancer drug in esophageal cancer.
Why promising? Tests a bispecific ADC approach in upper GI disease in randomized phase III.
What is not proven? Final results and global approval status need verification.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; enrollment closed. Read maturity from primary publication.
Cancer / population: Gastric / esophageal — Tekrarlayan veya metastatik özofagus skuamöz hücreli karsinom
Intervention: BL-B01D1 (izalontamab brengitecan)
Primary endpoint: Protokol tanımlı (PFS/OS)
Limitations: Sonuç yok; bölgesel program ≠ evrensel standart.